Lyell Immunopharma, Inc. Equity Securities, FV-NI, Unrealized Gain (Loss)
Lyell Immunopharma, Inc. (LYEL) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-06
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $0.00.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was $0.00.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was -$1.00K.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was -$1.00K.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was -$30.00K, a 200.00% decline from fiscal 2024.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was $30.00K.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | -$1.00K derived: sum of 3 quarters · filed 2026-08-06 | -$2.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | -$1.00K derived: sum of 2 quarters · filed 2026-05-06 | -$2.00K derived: sum of 3 quarters · filed 2026-05-06 | -$4.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$2.00K derived: sum of 2 quarters · filed 2026-03-12 | -$4.00K derived: sum of 3 quarters · filed 2026-08-06 | -$30.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$3.00K derived: sum of 2 quarters · filed 2026-08-06 | -$29.00K 10-Q · filed 2025-11-12 | -$46.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$28.00K 10-Q · filed 2026-08-06 | -$45.00K derived: sum of 3 quarters · filed 2026-08-06 | -$147.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$26.00K 10-Q · filed 2026-05-06 | -$43.00K derived: sum of 2 quarters · filed 2026-05-06 | -$145.00K derived: sum of 3 quarters · filed 2026-05-06 | -$1.53M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$119.00K derived: sum of 2 quarters · filed 2026-03-12 | -$1.50M derived: sum of 3 quarters · filed 2026-03-12 | $30.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.49M derived: sum of 2 quarters · filed 2025-11-12 | $47.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $149.00K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $1.53M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |